

UCLA

UCLA Previously Published Works

Title

Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers

Permalink

<https://escholarship.org/uc/item/3049q3fv>

Journal

Journal of the American Chemical Society, 142(40)

ISSN

0002-7863

Authors

Weil, Tatjana
Groß, Rüdiger
Röcker, Annika
[et al.](#)

Publication Date

2020-10-07

DOI

10.1021/jacs.0c06400

Peer reviewed

Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers

Tatjana Weil, Rüdiger Groß, Annika Röcker, Kenny Bravo-Rodriguez, Christian Heid, Andrea Sowislok, My-Hue Le, Nelli Erwin, Mridula Dwivedi, Stephen Bart, Paul Bates, Lukas Wettstein, Janis Müller, Mirja Harms, Konstantin Sparrer, Yasser B. Ruiz-Blanco, Christina Stuerzel, Jens von Einem, Sina Lippold, Clarissa Read, Paul Walther, Marco Hebel, Florian Kreppel, Frank-Gerrit Klärner, Gal Bitan, Michael Ehrmann, Tanja Weil, Roland Winter, Thomas Schrader, James Shorter, Elsa Sanchez-Garcia, and Jan Muench

J. Am. Chem. Soc., **Just Accepted Manuscript** • DOI: 10.1021/jacs.0c06400 • Publication Date (Web): 14 Sep 2020

Downloaded from pubs.acs.org on September 16, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supramolecular Mechanism of Viral Envelope Disruption by Molecular Tweezers

Tatjana Weil^{1#}, Rüdiger Groß^{1#}, Annika Röcker^{1#}, Kenny Bravo-Rodriguez^{2#}, Christian Heid³,
Andrea Sowislok³, My-Hue Le³, Nelli Erwin⁴, Mridula Dwivedi⁴, Stephen M. Bart^{5,6}, Paul
Bates^{5,6}, Lukas Wettstein¹, Janis A. Müller¹, Mirja Harms¹, Konstantin Sparrer¹, Yasser B.
Ruiz-Blanco,² Christina M. Stürzel¹, Jens von Einem⁷, Sina Lippold⁷, Clarissa Read^{7,8}, Paul
Walther⁸, Marco Hebel^{9,10}, Florian Kreppel¹¹, Frank-Gerrit Klärner³, Gal Bitan¹², Michael
Ehrmann¹³, Tanja Weil^{9,10}, Roland Winter⁴, Thomas Schrader^{3*}, James Shorter^{6,14*}, Elsa
Sanchez-Garcia^{2*} and Jan Münch^{1*}

¹Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany;

²Computational Biochemistry, Center of Medical Biotechnology, University of Duisburg-
Essen, Essen, Germany;

³Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany;

⁴Physical Chemistry I—Biophysical Chemistry, Faculty of Chemistry and Chemical Biology,
TU Dortmund University, Dortmund, Germany;

⁵Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, Pennsylvania, U.S.A.;

⁶Cell and Molecular Biology Graduate Group, Perelman School of Medicine at the University
of Pennsylvania, Philadelphia, U.S.A.;

⁷Institute of Virology, Ulm University Medical Center, Ulm, Germany;

⁸Central Facility for Electron Microscopy, Ulm University, Ulm, Germany;

⁹Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany

¹⁰Institute of Inorganic Chemistry I, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm,
Germany

¹¹Center for Biomedical Education and Research, University of Witten/Herdecke, Stockumer
Str 10, 58453 Witten, Germany

¹²Department of Neurology, David Geffen School of Medicine, Brain Research Institute, and
Molecular Biology Institute, University of California, Los Angeles, Los Angeles, United States;

¹³Microbiology II, Center of Medical Biotechnology, University of Duisburg-Essen, Essen,
Germany;

¹⁴Department of Biochemistry and Biophysics, Perelman School of Medicine at the University
of Pennsylvania, Philadelphia, U.S.A.

equal contribution

*For correspondence:

jan.muench@uni-ulm.de; elsa.sanchez-garcia@uni-due.de;

jshorter@pennterapeutics.com; thomas.schrader@uni-due.de;

Abstract

Broad-spectrum antivirals are powerful weapons against dangerous viruses where no specific therapy exists, as in the case of the ongoing SARS-CoV-2 pandemic. We discovered that a lysine- and arginine-specific supramolecular ligand (**CLR01**) destroys enveloped viruses, including HIV, Ebola and Zika virus, and remodels amyloid fibrils in semen that promote viral infection. Yet, it is unknown how **CLR01** exerts these two distinct therapeutic activities. Here, we delineate a novel mechanism of antiviral activity by studying the activity of tweezer variants: the “phosphate tweezer” **CLR01**, a “carboxylate tweezer” **CLR05**, and a “phosphate clip” **PC**. Lysine complexation inside the tweezer cavity is needed to antagonize amyloidogenesis and is only achieved by **CLR01**. Importantly, **CLR01** and **CLR05** but not **PC** form closed inclusion complexes with lipid head-groups of viral membranes, thereby altering lipid orientation and increasing surface tension. This process disrupts viral envelopes and diminishes infectivity, but leaves cellular membranes intact. Consequently, **CLR01** and **CLR05** display broad antiviral activity against all enveloped viruses tested, including herpesviruses, Measles virus, Influenza and SARS-CoV-2. Based on our mechanistic insights, we potentiated the antiviral, membrane-disrupting activity of **CLR01** by introducing aliphatic ester arms into each phosphate group to act as lipid anchors that promote membrane targeting. The most potent ester modifications harbored unbranched C4 units, which engendered tweezers that were approximately one order of magnitude more effective than **CLR01** and nontoxic. Thus, we establish the mechanistic basis of viral envelope disruption by specific tweezers and establish a new class of potential broad-spectrum antivirals with enhanced activity.

Introduction

Classical therapeutic strategies against viral infections focus primarily on inhibiting viral replication; in a “one bug – one drug” concept a specific protease and polymerase inhibitor is developed for each virus. However, for an increasing number of new viruses no treatment is available and there is an urgent need for innovation. A new approach has recently emerged which targets the virions themselves. This strategy has the potential to achieve broad antiviral activities especially against the constant threat of zoonoses, which are a major issue as evidenced by the newly emerged coronavirus, SARS-CoV-2. It involves external interference with the membrane fusion process which is essential for all enveloped viruses^{1,2}. Major avenues comprise inhibition of fusion proteins³ (e.g., by antiviral peptides [AVPs]⁴ or protein disulfide isomerase [PDI] inhibitors⁵) and modulation of membrane properties such as integrity (e.g., by virolytic peptides⁶), fluidity (e.g., by polyunsaturated ER - targeting liposomes [PERLs]⁷) or curvature (e.g., by rigid amphipathic fusion inhibitors [RAFIs]⁸). Finally, membrane properties essential for fusion are influenced by lipid oxidation which can be brought about by type II photosensitizers that oxidize unsaturated phospholipids (e.g. certain amphiphilic thiazolidines⁹). The molecular tweezers described in this work also modulate membrane integrity, albeit in a very subtle way: they specifically recognize lipid head groups and increase surface tension – a truly supramolecular mechanism, which operates on all enveloped viruses. The ‘molecular tweezer’ **CLR01** (Fig. 1a) is an inhibitor of aggregation and toxicity of amyloidogenic polypeptides containing arginine or lysine residues^{10–13}. Through specific binding to lysine and arginine residues, **CLR01** prevents polypeptide assembly into amyloid

1
2
3 and even remodels mature fibrils¹². We established that **CLR01** also inhibits the assembly of
4 seminal amyloids formed by specific proteolytic fragments of prostatic acid phosphatase (PAP)
5 and semenogelins (SEM)¹⁴. These fibrils are naturally present in human semen and markedly
6 enhance the infectivity of sexually transmitted viruses such as Human Immunodeficiency Virus
7 Type 1 (HIV-1)¹⁵⁻¹⁹, herpesviruses²⁰ and Ebola Virus (EBOV)²¹. **CLR01** also remodels
8 preformed PAP248-286 fibrils (termed SEVI for semen-derived enhancer of virus infection)
9 and PAP85-120 fibrils¹⁴. Semen amyloids are polycationic due to several arginine and lysine
10 residues and bind to the negatively charged membranes of viral particles and cells, which
11 increases viral attachment and augments fusion^{15,17,22,23}. Unexpectedly, we previously found
12 that **CLR01** not only antagonizes the infectivity-enhancing activity of seminal amyloids but
13 also exerts a direct antiviral activity against several enveloped viruses such as HIV-1, Hepatitis
14 C Virus (HCV), Herpes Simplex Virus type 2 (HSV-2), Human Cytomegalovirus (HCMV),
15 Zika Virus (ZIKV) and Ebola Virus^{14,24}. The antiviral activity is a consequence of the direct
16 interaction of **CLR01** with the membrane of the enveloped viral particle, which ultimately
17 results in the loss of virion integrity and hence infectivity^{14,24}. However, the precise antiviral
18 mechanism of **CLR01** remains unclear.
19
20
21
22
23
24
25

26 Due to their broad antiviral activity, **CLR01** and enhanced variants defined here are promising
27 leads for the development of a new class of potential antiviral drugs that specifically destroy
28 the structural integrity of enveloped viruses^{14,24}. Yet, although it is essential for future
29 therapeutic applications, the underlying mechanism of viral membrane destabilization is still
30 unknown¹⁴. To address this issue and to identify the structural requirements for suppressing
31 amyloid formation, we investigated how molecular tweezers, and a related clip-like molecule
32 with known supramolecular behavior, affect PAP248-286 amyloidogenesis and viral membrane
33 integrity. In addition to the “phosphate tweezer” **CLR01**, we analyzed the “carboxylate
34 tweezer”, **CLR05**, and the “phosphate clip”, **PC** (Fig. 1a). These three scaffolds were selected
35 for this mechanistic study because they represent prototypes that display different binding
36 profiles. Tweezers with phosphate, phosphonate or sulfate anions behave very similarly, but
37 **CLR01** is the least toxic among them. The carboxylate tweezer, **CLR05**, has a cavity (Fig. 1a)
38 but displays reduced affinity for lysine or arginine and thus we hypothesized might have
39 reduced ability to antagonize protein aggregation. The phosphate clip, **PC**, differs from **CLR01**
40 only in its cavity shape, which is more open due to the planar naphthalene side walls (Fig. 1a).
41 With these characteristic supramolecular host structures, we hoped to probe and separate the
42 different mechanistic paths of antiviral and anti-amyloid action. Using a synergistic approach
43 combining computational chemistry, cell biology, virology, supramolecular binding studies and
44 biophysics, we elucidated both the anti-amyloid and antiviral mechanisms. We found that lysine
45 complexation inside the tweezer cavity is required to inhibit amyloidogenesis. The formation
46 of inclusion complexes with lipid head-groups of the viral membrane increases surface tension
47 and disrupts the viral membrane resulting in diminished infectivity. Our findings explain the
48 origin of viral envelope destabilization by tweezers. With the identification of **CLR05** as an
49 antiviral agent, in addition to **CLR01**, we establish these supramolecular ligands as a new class
50 of broadly active antiviral compounds. Based on these mechanistic insights, a series of
51 advanced new tweezer derivatives were designed with additional lipid anchors. These novel
52 tweezers exhibited potentiated antiviral activity compared to the parental **CLR01** scaffold.
53
54
55
56
57
58
59
60

Results

CLR05 and PC have no anti-amyloid activity

To define the mechanism of **CLR01** action, we first established the activity of **CLR05** and **PC**. The tweezers (**CLR01** and **CLR05**) and the clip (**PC**) share the same central unit, but carry distinct sidewalls, which form cavities with typical shapes thus enabling their specific binding profiles (Fig. 1a, Table 1). **CLR01** forms inclusion complexes with lysine residues and to a lesser extent with arginine²⁵. **CLR05** is structurally similar to **CLR01**, but the hydrogen phosphate substituents are replaced with methylene carboxylate groups (Fig. 1a). The phosphate clip, **PC**, with its almost parallel naphthalene sidewalls was designed for planar aromatic guests such as cationic cofactors, which are preferentially accommodated inside its cavity^{26,27} (Fig. 1a). In sharp contrast, inclusion of aliphatic cationic guests such as Lys or Arg inside **PC** is less favored and only occurs with low affinity²⁸ (Table 1).




Fig. 1. The molecular tweezer CLR05 and the clip PC neither inhibit amyloid assembly nor remodel amyloid fibrils. (a) Chemical structures of the hydrogen phosphate tweezer **CLR01**, methylene carboxylate tweezer **CLR05** and the naphthalene phosphate clip **PC**. **(b, c)** **CLR05** and **PC** do not inhibit amyloid fibril formation. **(b)**

PAP248-286 (1 mM), PAP85-120 (1 mM) and SEM1(45-107) (0.5 mM) peptides were incubated with the indicated concentrations of **CLR01**, **CLR05**, **PC** or buffer and agitated at 1400 rpm at 37°C. After 24 h (PAP85-120) or 72 h (PAP248-286 and SEM1(45-107)) fibrillization was assessed using the amyloid-binding dye Thioflavin-T (ThT). Values represent means \pm SEM ($n = 3$). (c) PAP248-286 (1 mM) was incubated with **CLR01** (1 mM), **CLR05** (1 mM), **PC** (1mM) or buffer and agitated at 1400 rpm at 37°C. After 72 h fibrillization was assessed by transmission electron microscopy (TEM). Bar, 250nm. (d) PAP248-286 (1 mM, plus 2% wt/wt SEVI fibrils), were incubated with the indicated concentrations of **CLR01**, **CLR05**, **PC** or buffer and agitated at 1400 rpm at 37°C. After 48 h fibrillization was assessed using the amyloid-binding dye Thioflavin-T (ThT). Values represent means \pm SEM ($n = 3$). (e) **CLR05** and **PC** do not remodel preformed fibrils. SEVI, PAP85-120 fibrils or SEM1(45-107) fibrils (20 μ M) were incubated with the indicated concentrations of **CLR01**, **CLR05** or **PC**. After 2 h at 37°C, ThT fluorescence was measured. Values represent means \pm SEM ($n = 3$). (f) SEVI fibrils (20 μ M) were incubated with **CLR01** (1mM), **CLR05** (1mM) or **PC** (1mM). After 2 h at 37°C, reactions were processed for TEM. Bar, 250nm. For **b**, **d**, **e**, one-way ANOVA (non-parametric, grouped), followed by Dunnett's multiple comparison tests were applied to compare the compound-treated samples to the respective buffer control

Table 1. Lysine and arginine affinities of the three host molecules (**CLR01**, **CLR05**, **PC**) determined by fluorescence titrations in 75 mM phosphate buffer (pH 7.4).

Host	K_d [μ M]	
	Ac-Lys-OMe	Ac-Arg-OMe
CLR01 ²⁵	17	22
PC ²⁹	4670	1760
CLR05 ²⁵	1160	1390

In solution, **CLR05** forms both, chelates and inclusion complexes, with Lys/Arg residues²⁵ (Supplementary Fig. 1a). However, it is important to clarify **CLR05** behavior in a protein environment. In line with its experimentally determined low Lys and Arg affinities in solution²⁵ (Table 1), our computational studies of the **CLR05** interaction with the prototype amyloidogenic peptide in semen, PAP248-286, showed that **CLR05** has a reduced ability to form inclusion complexes with Lys or Arg, as compared to **CLR01** (Supplementary Figs. 1b and 1d). The global minima on the peptide-tweezer free energy surfaces obtained with extended-system Adaptive Biasing Force (eABF) calculations indicate that binding of **CLR05** to residues at the N-terminal (K251) and C-terminal (K281 and K282) regions of PAP248-286 is not favored, whereas K253 and R257 form distorted, unstable inclusion complexes (Supplementary Fig. 1b and 1c). In addition, free energy perturbation calculations indicate that **CLR01** forms more stable inclusion complexes with almost all Lys or Arg residues in PAP248-286, as compared to **CLR05** (Supplementary Fig. 1d). The only exception was R273, which formed a more stable inclusion complex with **CLR05** than with **CLR01** (Supplementary Fig. 1d). However, R273 is not located in any of the hexapeptides predicted to form self-complementary β -sheets, termed steric zippers, which are anticipated to contribute to SEVI fibril formation^{14,19}. Importantly, unlike **CLR01**¹⁴, **CLR05** fails to interact effectively with K281 and K282, which are located in two potent steric zippers at the C-terminal end of PAP248-286¹⁹ and form part of the stable cross- β SEVI fibril core defined by hydrogen-deuterium exchange³⁰. Collectively, these findings predict that **CLR05** would lack the anti-amyloid

1
2
3 activity of **CLR01**. Similarly, we expected that **PC** would not show anti-amyloid activity since
4 its affinity for Lys/Arg is even lower than that of **CLR05** (Table 1).
5
6

7
8 For the experimental evaluation of these predictions, we investigated the effects of **CLR01**,
9 **CLR05** and **PC** on the formation of semen amyloid fibrils. Indeed, unlike **CLR01**, neither
10 **CLR05** nor **PC** inhibit spontaneous assembly of PAP248-286, PAP85-120 and SEM1(45-107)
11 fibrils (Fig. 1b, c). Moreover, **CLR05** and **PC** did not inhibit fibrillization of PAP248-286 that
12 was seeded by preformed SEVI fibrils (Fig. 1d). Likewise, **CLR05** and **PC** were unable to
13 remodel preformed SEVI or PAP85-120 fibrils (Fig. 1e, f), and none of the scaffolds could
14 remodel SEM1(45-107) fibrils (Fig. 1e)¹⁴. Thus, in contrast to **CLR01**, **CLR05** has no anti-
15 amyloid activity. As expected, due to its architecture, **PC** does not bind aliphatic guests and did
16 not affect fibril formation by any of the peptides.
17
18
19
20

21 **CLR05 and PC do not prevent the formation of virus-fibril complexes nor abrogate viral** 22 **infection enhancement**

23 **CLR01** not only has anti-amyloid activity but also prevents the formation of complexes
24 between seminal fibrils and HIV-1 particles¹⁴. In contrast, we discovered that **CLR05** and **PC**
25 do not inhibit complexation of YFP-tagged virions with the three types of seminal amyloids
26 (Fig. 2a). We next determined the effect of **CLR05** and **PC** on cell growth and found that
27 concentrations of up to 250 μM were well tolerated (Supplementary Fig. 2a). Thus, all
28 subsequent experiments were performed with **CLR05** and **PC** concentrations $\leq 150 \mu\text{M}$ to
29 exclude any confounding effects caused by residual cytotoxicity. To determine the effect of
30 **CLR05** and **PC** on amyloid-mediated infectivity enhancement, SEVI fibrils were incubated
31 with PBS or with a 20-fold molar excess of each tweezer/clip, then mixed with HIV-1 and this
32 solution was used to inoculate target cells. SEVI fibrils increased HIV-1 infection in a dose-
33 dependent manner as described previously¹⁵, and **CLR01** eradicated this effect¹⁴ (Fig. 2b). In
34 the presence of **CLR05**, however, the infectivity enhancing activity of the fibrils was reduced
35 but not abrogated. **PC** was completely inactive in antagonizing the infection enhancing effects
36 of SEVI (Fig. 2b). The experiment was also performed with PAP85-120 and SEM1(45-107)
37 fibrils. Again, **CLR01** abrogated infectivity enhancement, **CLR05** showed an intermediate
38 effect and **PC** was inactive (Supplementary Fig. 2b-d). Since **CLR05** has no anti-amyloid
39 activity (Fig. 1b-1d), these data suggest that reduced infection rates are due to a direct antiviral
40 activity of **CLR05**.
41
42
43
44
45
46
47
48

49 **CLR05 has direct anti-HIV activity**

50 Next, we tested **CLR01**, **CLR05** and **PC** for a direct effect on virus infection. First, HIV-1
51 particles were incubated with tweezers, clip or buffer, and then used for infection. **PC** did not
52 exert any antiviral activity whereas **CLR05** inhibited HIV-1 infection with a half-maximal
53 inhibitory concentration (IC_{50}) of $\sim 41 \mu\text{M}$, which is ~ 2.4 -fold higher than the IC_{50} of **CLR01**
54 ($\sim 17 \mu\text{M}$) (Fig. 2c, Supplementary Fig 2e). Like **CLR01**, **CLR05** did not inhibit HIV-1
55 infection if target cells were pre-exposed to the tweezer, demonstrating that both tweezers target
56 the virus itself (Fig. 2d).
57
58
59
60

Tweezers and clip form inclusion complexes with lipid head groups

To understand the antiviral effects of **CLR01** and **CLR05** at the molecular level, we investigated if the tweezers and the clip directly interact with the lipid head groups in the viral envelope, first by molecular dynamics simulations, then by NMR titration. The composition of viral envelopes greatly varies with the type of virus, the host cell membrane and the cell type. Generally, however, viral membranes tend to be enriched in lipids found in lipid rafts (lipid microdomains enriched in glycosphingolipids and cholesterol) such as sphingomyelin (SM)^{31,32}, since viruses bud directly from lipid-raft domains of cell membranes³³. Thus, lipidomics analyses provide experimental evidence of a special enrichment of HIV-1 viral membranes in SM and Cholesterol (Chol), phosphatidylserine (PS) and plasmalogen-phosphatidylethanolamine (pl-PE), all leading to




Fig. 2. CLR05 anti-HIV-1 activity. (a) **CLR05** and **PC** do not prevent formation of virus-fibril complexes. Fibrils (200 μg/ml) were incubated with buffer, **CLR01**, **CLR05** or **PC** in 20-fold molar excess for 5 min and stained with Proteostat Amyloid Plaque Detection Kit. MLV-Gag-YFP particles (green) were added 1:2 and incubated with the stained fibrils (red) for 5 min before samples were analyzed via confocal microscopy. Scale bar: 5 μm. (b) **CLR05** but not **PC** decreases the HIV-1 enhancing activity of SEVI. Fibrils were incubated with buffer or a 20-fold molar excess of **CLR01**, **CLR05** or **PC** for 10 min at room temperature. After preparing 5-fold dilution series of the mixtures, HIV-1 was added and TZM-bl cells were inoculated with these samples. Values represent % β-galactosidase activities (mean) compared to cells infected with virus only and are obtained from triplicate infections ± SEM (n=9). Numbers above the symbols indicate n-fold enhancement of infection. (c, d) **CLR05** blocks HIV-1 infection by targeting the virus. (c) HIV-1 was incubated with **CLR01**, **CLR05**, **PC** or buffer for 10 min at 37°C before it was added to TZM-bl cells. Three days post infection (dpi), infection rates were quantified by measuring β-galactosidase activity in cellular lysates. Values represent % infection (mean) compared to buffer

1
2
3 control \pm SD (n=3). (d) TZM-bl cells were incubated with the indicated concentrations of **CLR01**, **CLR05**, **PC** or
4 buffer for 1 h at 37°C. Cell supernatants were discarded, and cells were infected with CCR5-tropic HIV-1 NL4-3.
5 Values represent % infection (mean) compared to buffer control \pm SD (n=3).
6

7
8 more rigid membranes characteristic of lipid rafts³¹. A similar case can be made for the
9 influenza virus, which is likewise enriched in SLs (sphingolipids) and cholesterol, irrespective
10 of the investigated producer cell line³². Thus, viral membranes tend to resemble the lipid-raft
11 microdomains from whence they originate^{31,34–37}.
12


13
14 For our calculations, we selected three abundant lipids which occur in both eukaryotic cells and
15 virions: dipalmitoylphosphatidylcholine (DOPC), sphingomyelin (SM) and cholesterol (Chol).
16 To account for the different degree of lipid rafts, we composed a simple bilayer containing 120
17 DOPC lipids per leaflet, and a mixed bilayer containing 54, 30 and 36 molecules per leaflet of
18 DOPC, sphingomyelin (SM) and cholesterol (Chol), respectively. We then studied the
19 interaction of **CLR01**, **CLR05** and **PC** with these model membranes using unbiased molecular
20 dynamics simulations. Our simulations contained nine molecules of tweezers or clip, initially
21 placed 4 Å above the membrane (example shown for **CLR01** in Supplementary Fig. 3a). Our
22 results indicate that **CLR01**, **CLR05** and **PC** form inclusion complexes with the head-groups
23 of DOPC and SM lipids, in both the DOPC and the mixed bilayer (Supplementary Tables 1-4,
24 Supplementary Figs. 4a-c). Importantly, after forming an inclusion complex, **CLR01** and
25 **CLR05** induce preferential orientations of the complexed lipid head groups (Fig. 3a and 3b),
26 unlike **PC** (Fig. 3a and 3c). Upon inclusion inside **CLR01** or **CLR05**, the lipid head groups
27 adopt an orientation nearly perpendicular to the normal of the membrane (z-axis) (the angle
28 with respect to the z-axis is $\sim 90^\circ$, Fig. 3b). This distortion is dictated by the upright orientation
29 of the amphiphilic tweezer inside the membrane whose cavity must be entered from the side.
30 Consequently, the whole tweezer is inserted in the most external layer of the membrane, formed
31 by the polar ammonium and phosphate groups of its phospholipid components (Fig. 3b). This
32 tweezer orientation likely induces local stress around the binding site thus weakening the
33 bilayer. By contrast, in the presence of **PC**, the lipid head group remains aligned nearly parallel
34 to the normal of the membrane (z-axis) (Fig. 3c). This alignment can occur because the clip
35 cavity is more open than the tweezer cavity, which enables facile lipid inclusion into the clip
36 cavity by vertical entry.
37
38
39
40
41
42
43
44
45

46 To further explore the finding that the tweezers encapsulate lipid head-groups and do not
47 penetrate into the membrane interior, the free energy changes for the insertion of **CLR01**,
48 **CLR05** and **PC** into a DOPC or a mixed bilayer were calculated using the eABF scheme
49 (Supplementary Fig. 3 shows **CLR01** as a representative case). For both bilayers, the minimum
50 in the one-dimensional Potential of Mean Force (PMF) profile corresponds to the tweezers
51 forming an inclusion complex with a head-group of a lipid located at the surface of the
52 membrane (as indicated by position 2 in Supplementary Fig. 3b) rather than inside the bilayer
53 where the free energy is much higher (position 3, Supplementary Fig. 3b). Although the free
54 energy differences between the tweezers in solution (position 1, Supplementary Fig. 3b) and
55 the complex at the surface of the membrane (position 2, Supplementary 3b) are very small, the
56 MD simulations indicate that the tweezer-lipid complexes do form, albeit not as efficiently as
57 the **PC**-lipid complexes (Supplementary Table 1). Importantly, the free-energy calculations
58
59
60


1
2
3 establish that **CLR01**, **CLR05** and **PC** are unlikely to penetrate deep inside or cross the
4 bilayers. The key to the antiviral activity of the tweezers most likely relates to their effect on
5 the lipid orientation, as discussed above, and/or a preference of the tweezers toward lipids like
6 SM, which are characteristic of viral membranes.
7
8

9
10 Here, to explore if **CLR01** has a certain preference for raft-forming lipids, we performed
11 quantum mechanics/molecular mechanics (QM/MM) calculations. Our results indicate that the
12 **CLR01-SM** complex is indeed more stable (in terms of electronic relative energy) than the
13 **CLR01-DOPC** complex (Supplementary computational details, Supplementary Fig. 5a and
14 5b). To clarify if this selective stabilization of the **CLR01-SM** complexes is related to the
15 disruption of interactions between the lipid molecules and the solvent or due to the membrane
16 environment, we also calculated **CLR01-SM** and **CLR01-DOPC** inclusion complexes in
17
18
19

20 **a**



31 **b**



32 **c**




Figure 3. Computational modeling of the interactions of the tweezers and clip with lipid membranes. (a) The distribution of the values adopted by the angle indicating the relative orientation of the lipid head-group with respect to the normal of the membrane model (z axis) provides evidence that the orientations of the lipids are different upon interaction with the tweezers with respect to the clip. **(b)** Upon binding to a lipid in the bilayer, the tweezers (**CLR01** is shown here as representative case) enforce a conformation of the lipid head-group parallel to the bilayer surface, raising surface tension. **(c)** By contrast, the lipid head-group bound to **PC** remains perpendicular to the bilayer surface in a tension-free conformation. An enlargement of the binding region is shown for both b) and c). **CLR01** and **PC** are depicted as sticks with carbon atoms in gray, oxygen in red and phosphorous in tan. DOPC is shown in blue, PSM in pink and CHL1 in green. The lipid bound to **CLR01** or **PC** is highlighted in yellow. The dotted line is traced along the vector between the centers of the phosphate and the ammonium groups in the lipid head.

an explicit water environment using the same computational protocol as in the membrane simulations. We found that the **CLR01-SM** complex is more stable than the **CLR01-DOPC** complex also in solution (Supplementary Fig. 5b). Our results suggest that the hydration of the lipid polar head groups is the main determinant of the higher affinity of the tweezers for SM. This finding can be rationalized by the fact that the lipid bilayer is commonly hydrated at its most external regions composed of quaternary ammonium and phosphate groups. The binding of the tweezers implies desolvation of the ammonium moiety and partial desolvation of the phosphate group of the lipid. Hence, the stabilization of the inclusion complex is determined by competing forces between electrostatic and dispersion interactions with the tweezers and the solvation of the polar groups of the lipid. Notably, the phosphate group of SM establishes a stabilizing intramolecular hydrogen bond with the hydroxyl group next to it (Supplementary Fig. 5c), unlike DOPC. This interaction diminishes the desolvation cost in SM thereby stabilizing the **CLR01-SM** complex. Conversely, the DOPC molecules depend completely on the surrounding water to stabilize the phosphate group, resulting in a higher desolvation cost for the formation of **CLR01-DOPC** inclusion complexes. Although lipid rafts are composed of various different rigid lipids, such effects may contribute to a preferred complexation of prominent raft lipids by the tweezers, and contribute to their low toxicity towards cells relative to enveloped viruses. Taken together, our modeling experiments suggest an explanation for the preferential destabilization of viral membranes by molecular tweezers: they reveal that lipid head groups are included in the tweezer cavity, which causes alterations in lipid orientation that destabilize the membrane. Indeed, the formation of a supramolecular complex allows for the insertion of the tweezers in the hydrophilic region of the outer membrane leaflet. Consequently, membrane tension will increase in both in cellular and viral membranes. However, if viral membranes are enriched in lipid rafts, this effect will elevate their tension above a tolerable threshold and lead to membrane rupture.

NMR titrations corroborate the formation of inclusion complexes with lipids

To complement the computational studies, we proceeded to structural investigations. ^1H NMR spectra of the 1:1 complexes (0.33 mM) between hosts (tweezers and clip) and lipids (SM, DOPC) revealed significant complexation-induced up-field shifts for the protons of the entire trimethylammonium choline head group, indicating at least partial inclusion inside the host cavities (Fig. 4a). Fig. 4 shows the example of phosphosphingomyelin interacting with **CLR01**. All the other combinations are presented in Supplementary Figs. 6a-f. Attempted fluorescence titrations in methanol gave very small changes in host emission intensity, too small for reliable quantification. After careful optimization, a comparative NMR study was executed in d_4

methanol (due to the low lipid solubility in water), with all three host molecules and DOPC as well as SM as guests. Binding isotherms produced excellent fits by nonlinear regression (Fig. 4b), and revealed weak affinities resulting from K_d values in the low millimolar regime (Table 2). Maximum complexation-induced ^1H NMR chemical upfield shifts reached remarkable $\Delta\delta$ values of up to 4 ppm, and demonstrated the efficient inclusion of the entire choline lipid head group inside the respective host cavities (Fig. 4c).

We asked if the weak affinities originate from the steric bulk of the trimethylammonium head-group and turned to trimethyllysine: NMR spectra for **CLR01** with this related guest molecule reached comparable upfield shifts for the NMe_3^+ cation, but titrations maintained the high lysine affinity ($K_d \sim 10 \mu\text{M}$). We conclude that the close proximity between the choline phosphate ester




Figure 4. Tweezers and clip form inclusion complexes with lipid head-groups. (a) Complex formation between **CLR01** and sphingomyelin (SM) monitored by NMR spectroscopy: stacked plot of ^1H NMR spectra showing SM with increasing amounts of added **CLR01**. Colored signals represent the choline head-group inserted into the tweezer cavity. (b) Corresponding binding curve for the $\text{N}(\text{Me})_3^+$ signal with the resulting affinity (K_A/K_D) and $\Delta\delta_{\text{max}}$ value obtained from nonlinear regression. (c) Lewis structure of **CLR01** with inserted choline moiety from PSM inside; CH_2/CH_3 groups inside the tweezer cavity are color-coded because they undergo large upfield shifts.

Table 2: Maximum complexation-induced chemical ^1H NMR shift changes ($\Delta\delta_{\text{max}}$ [ppm]) of the $\text{N}(\text{Me})_3^+$ protons and dissociation constants K_D obtained from NMR titrations of lipids (PSM, DOPC) with hosts (**CLR01**, **CLR05**, **PC**). Lipid concentration was 0.33 mM in d_4 -methanol.

Host	$\Delta\delta_{\text{max}}$ [ppm]		K_d (1:1)	
	SM	DOPC	SM	DOPC
CLR01	2.92	4.36	7.9 mM	14 mM
PC	0.89	1.45	7.0 mM	13 mM
CLR05	1.73	0.96	61 mM	37 mM

anion and the anionic substituents of the tweezers or clip severely limits lipid affinities, whereas the extended alkylammonium arms of Lys or Arg fit well into the tweezer cavity, and most likely benefit from large dispersive and electrostatic attraction. **CLR01** and **PC** produce comparable affinities towards both lipids (SM \sim 7 mM; DOPC \sim 14 mM) (Table 2). By contrast, **CLR05** is a much weaker lipid binder (\sim 40-60 mM), most likely, because it also chelates the choline head group externally, as evidenced by the modest complexation-induced ^1H NMR upfield shifts compared to **CLR01** (Fig. 4, Supplementary Fig. 6). This finding agrees well with poor lysine inclusion by **CLR05**²¹ and with the simulations (binding events and free energy calculations) (Supplementary Fig. 5).

CLR05 selectively disrupts raft-rich membranes

To further investigate the consequences of the tweezer/clip interaction with lipid bilayers, we took advantage of two types of engineered giant unilamellar vesicles (GUVs) of \sim 5-40 μm in diameter. In parallel with the calculations, one type of GUVs consisted only of DOPC. The other type of GUVs was composed of a 45/25/30 mol% mixture of DOPC, SM and Chol as a membrane model with a large content of lipid rafts. These models are not intended to exactly recreate viral or eukaryotic cell membranes per se, whose lipid composition greatly varies and is much more complex. Instead, they aim at testing whether an elevated lipid raft content of representative lipids enriched in viral membranes renders them more susceptible to disruption by tweezers.

The different lipid phases were marked with fluorescent lipid analogs that segregated into the liquid-disordered (l_d) (red channel) or the liquid-ordered (l_o) (green channel) phase when viewed via fluorescence microscopy (Fig. 5a and b). In addition, the GUVs were loaded with the water-soluble dye ATTO 647 (blue channel). Exposure of DOPC vesicles to **CLR05** (Fig. 5a, bottom panel) or **PC** (Fig. 5b, bottom panel) did not affect vesicle morphology and did not elicit dye leakage. However, when **CLR05** was added to DOPC/SM/Chol vesicles, the l_o domains started to bud from the GUVs and most of them had pinched off after \sim 15-30 min of incubation, with concomitant dye leakage from the GUVs (Fig. 5a, top panel). However, in contrast to **CLR01**, which destroys the mixed vesicles¹⁴, **CLR05** partially preserved GUV membrane integrity (Fig. 5a, top panel). In sharp contrast, the clip did not permeabilize either of the GUV species even after 60 min incubation (Fig. 5b). Under identical conditions, **CLR01** had a much more drastic effect: While the DOPC vesicles remained all intact, already after 5 minutes all membranes of mixed vesicles were disrupted and the dye was lost completely¹⁴.




Figure 5. CLR05 destroys raft-like lipid vesicles. (a, b) Confocal fluorescence microscopy images of lipid raft enriched GUVs consisting of pure DOPC (lower panel) or a DOPC/SM/Chol (45/25/30 mol%) lipid mixture (upper panel) labeled with N-Rh-DHPE (l_d lipid phase, red channel) and Bodipy-Chol (l_o lipid phase, green channel) and filled with Atto 647 dye (blue channel). 150 μ M of CLR05 (a) or PC (b) were added and incubated for indicated

1
2
3 times. Scale bar: 5 μm . (c) Liposome dye leakage assay of DOPC/SM/Chol (45/25/30 mol%) liposomes extruded
4 to 200 nm size filled with 50 mM carboxyfluorescein. Compounds were added after measuring baseline
5 fluorescence for 5 min (first dotted line) and after 30 min incubation with compounds, Triton X-100 was added to
6 1% final concentration to measure fluorescence intensity after full leakage in each well (second dotted line).
7 Fluorescence values were baseline-subtracted (before addition of compounds) and normalized to maximum
8 fluorescence obtained after addition of Triton X-100. Values represent means \pm SD ($n = 3$). (d) AFM images of a
9 DOPC/SM/Chol (45/25/30 mol%) lipid membrane on mica before injection (0 min) and after injection of 150 μM
10 **CLR05** (left) or **PC** (right) in 10 mM NaH_2PO_4 , pH 7.6 into the AFM fluid cell.

11
12 To study membrane disruption in the context of virus-like vesicles, mixed-lipid
13 (DOPC/SM/Chol, 45/25/30 mol%) liposomes were prepared and loaded with
14 carboxyfluorescein at a self-quenching concentration of 50 mM. In this setup, an increase in
15 fluorescence indicates membrane disruption due to dye leakage and dilution below self-
16 quenching concentrations in the surrounding medium. **CLR05** and **CLR01** but not **PC** induced
17 dye leakage in a dose-dependent manner within few minutes (Fig. 5c). **CLR05** was less potent
18 than **CLR01** (Fig. 5c). **CLR01** rapidly induced full leakage of liposomes at 150 μM
19 concentration, whereas **CLR05** resulted in a maximal leakage of only 78% after 30 min of co-
20 incubation at the same concentration (Fig. 5c, Supplementary Fig. 7a). The previously reported
21 antivirally inactive spacer molecule CLR03¹⁴ behaved similarly as **PC** and did not induce
22 leakage (Supplementary Fig. 7a-c).

23
24 Atomic force microscopy (AFM) of the heterogeneous model bio-membrane confirmed that the
25 line tension at the phase interface is increased in the presence of **CLR05** (Fig. 5d). As a result,
26 the size of the l_o domains increased, which is accompanied by a slight increase in the difference
27 in domain height thickness. This effect is likely due to an increased line tension at the boundary
28 between the ordered and disordered domains induced by **CLR05** attachment. AFM experiments
29 demonstrated that addition of **PC** produced a small increase in height difference between the l_o
30 and l_d phase as well; however, changes in the lateral membrane organization were small (Fig.
31 5d). This finding further confirms that **PC** binds to the lipid bilayer although it does not disrupt
32 it, pointing to a subtle but profound difference in its mode of action compared to the tweezers,
33 **CLR05** and **CLR01**, which disrupt membranes enriched in SM and Chol, such as those of
34 enveloped viruses, as predicted by the biomolecular simulations (Fig. 3).

35
36 We conclude that experiments on model membranes strongly support the suggested mechanism
37 of membrane destabilization by supramolecular docking of designed ligands to the lipid head
38 groups and subsequent increase in surface tension. Importantly, lipid rafts are enriched in viral
39 membranes, which makes them more susceptible to disruption by tweezers. Indeed, a single
40 rupture of the viral membrane destroys the virus irreversibly. By contrast, cells can actively
41 repair their membranes after lipid-raft disruption.

42 **CLR01 induces distortions in viral membrane**

43
44 We next visualized the effect of the tweezers on the envelope of virus particles. We first
45 analyzed HIV-1 and ZIKV by cryo-transmission electron microscopy (cryo-TEM) but
46 encountered problems at detecting a sufficient number of the relatively small virions (data not
47 shown). We therefore switched to HCMV, a relatively large virus, which is antagonized by
48 **CLR01**¹⁴. Cryo-TEM analysis of untreated HCMV virions showed \sim 200 nm-sized particles
49
50
51
52
53
54
55
56
57
58
59
60

with a protein-rich tegument and an intact membrane in 78.1 % of all analyzed images (n=32) (Fig. 6a, Supplementary Fig. 8a and Supplementary Table 5). Upon incubation of HCMV with **CLR01** for 30 min, we observed distortions in the viral membrane in 84.6 % of the analyzed samples (n= 39) (Fig. 6a, Supplementary Fig. 8a and Supplementary Table 5). Interestingly,




Figure 6. CLR01 destroys the HCMV envelope and exerts broad antiviral activity against enveloped virus infection. (a) Cryo-TEM of HCMV virions after treatment with medium (1) or 50 μM CLR01 (2a-b) for 30 min at 37°C. Important virion structures are indicated in image 1. CLR01-treated virion in 2a-b shows a discontinuous envelope and is decorated with electron-dense material at these sites (white arrowhead). Scale bar is 100 nm. (b) Antiviral activity of tweezers and clip against enveloped (ZIKV, HSV-1, HSV-2, HCMV, MV, IAV) and non-enveloped virus infection (EMCV). ZIKV MR766 was incubated for 30 min at 37°C with buffer or 0.2-150 μM CLR01, CLR05 or PC before these mixtures were added to Vero E6 cells. 2 dpi, cell-based ZIKV

1
2
3 immunodetection was performed. Values represent means \pm SEM (n=3). HSV-1 and HSV-2 were incubated for
4 30 min with compounds and then added to Vero E6 cells. After 1 h incubation, media were changed, 12 h post
5 infection, cells were fixed, and infection rates were quantified via staining for the HSV protein ICP0. Values
6 represent means of % infection \pm SD (n=3). Measles virus was exposed to compounds for 30 min at 37°C before
7 these mixtures were added to A549 cells. After 4h, cells were washed and medium was replaced. 2 dpi, infection
8 rates were quantified by staining with an FITC-coupled MV antibody and measuring mean fluorescence intensities
9 on a plate reader. Values represent means \pm SD (n=6). Influenza strain A/PR/8/34 was incubated with 0-150 μ M
10 **CLR01**, **CLR05** or **PC** for 30 min at 37°C before the mixtures were used to infect A549 cells. After 1h, cells were
11 washed and medium was changed. After 48 hours, infectivity rates were determined by measuring neuraminidase
12 activity in cellular lysates (MUNANA assay). Values represent means \pm SD (n=3). EMCV was incubated for 30
13 min at 37°C with buffer or different concentrations of **CLR01**, **CLR05** or **PC** before it was added to HFF cells.
14 Two days later, cytopathic effect (percentage of detached cells) was quantified by MTT assay and used to calculate
15 infection rates. Values represent means \pm SD (n=3).

16
17 these distortions resulted in the leakage of the gel-like tegument to the outside of the virus, but
18 not an entire loss of the structural integrity of the viral particle. Viral DNA release assays
19 confirmed that **CLR01** does not cause an entire destruction of the HCMV particle
20 (Supplementary Fig. 8b). These data are in contrast to those obtained with HIV-1 and ZIKV^{14,24}
21 where **CLR01** and **CLR05** resulted in complete destruction of the virions (Supplementary Fig.
22 9). However, this discrepancy is likely explained by the fact that HCMV is a relatively stable
23 virus because of the numerous interactions of the viral glycoproteins with the tegument,
24 explaining its partial resistance even against detergents (Supplementary Fig. 8b). To assess
25 whether CLR01 or CLR05 might induce virus aggregation we utilized fluorescent nanoparticle
26 tracking of virus-like particles. We did not see any aggregation of virus-like particles induced
27 by CLR01, CLR03, CLR05, or PC (Supplementary Fig. 10). By contrast, SEVI fibrils induced
28 aggregation of viral particles as expected (Supplementary Fig. 10). These findings suggest that
29 CLR01 and CLR05 disrupt viral membranes without inducing aggregation of the virus.

35 36 **CLR01 and CLR05 are broad-spectrum antivirals**

37 If tweezers act against viral membranes, they should be generally active against enveloped
38 viruses. Indeed, we found that **CLR05** abrogated infection of pseudo-viruses carrying the
39 glycoproteins of Marburg, Ebola, Rabies or SARS-coronavirus 1 (Supplementary Fig. 11a), as
40 previously shown for **CLR01**²⁴. Moreover, we found that both tweezers inhibited infection by
41 pseudo-viruses harboring the spike glycoprotein of SARS-CoV-2, the causative agent of the
42 ongoing COVID-19 pandemic, whereas PC had a modest effect at high concentrations
43 (Supplementary Fig. 11b). **CLR01** and **CLR05** also inhibited infection of replication-
44 competent ZIKV, HSV-1, HSV-2, Measles virus (MV) and Influenza virus (Fig. 6b) with a
45 mean IC₅₀ of 19.3 μ M for **CLR01**, and 38.1 μ M for **CLR05**. The clip did not affect infectivity
46 of any of these viruses except for a modest effect on MV (Fig. 6b). Importantly, neither **CLR01**
47 nor **CLR05** reduced infection by non-enveloped Adenovirus (Supplementary Fig. 11c) or
48 Encephalomyocarditis virus (Fig. 6b). Thus, our results indicate that **CLR01** and **CLR05** are
49 both broad-spectrum inhibitors of pathogenic enveloped viruses. We cannot exclude at this
50 point, that **CLR01** binding to lysine-rich tracts of viral proteins may also influence virus
51 attachment to the host cell and thereby decrease infectivity. However, the structure of these
52 glycoproteins varies greatly between different viruses, and interference with protein
53 interactions usually requires higher affinities than those displayed by **CLR01** (>20 μ M).
54 Furthermore, electron microscopy demonstrates a direct destabilization of the viral envelope by
55
56
57
58
59
60

1
2
3 **CLR01** (Fig. 6a)¹⁴. Indeed, there has so far been no exception from the empirical rule that
4 molecular tweezers disrupt the membrane of all enveloped viruses, but are inactive against non-
5 enveloped viruses.
6
7

8 **Additional lipid anchors significantly improve the antiviral activity of CLR01**

9

10 If the mechanistic picture of membrane destabilization by direct tweezer docking onto lipid
11 headgroups is correct, additional lipid anchors on the tweezer should enhance this interaction
12 and yield more potent scaffolds. In a first series of advanced tweezers, we introduced a wide
13 range of aliphatic ester arms into each phosphate group of **CLR01** (Fig. 7a). These
14 modifications were accomplished by activation of the phosphoric acid with trichloroacetonitrile
15 (TCA), which can be controlled in pyridine to occur only once¹⁴. The length of these additional
16 lipid anchors was varied between C1 and C16 chains, and initial antiviral activities were
17 assessed with the same experiments on HIV-1 as described for **CLR01**, **CLR05** and **PC**.
18 Intriguingly, most tweezer derivatives are more effective than their parent compound **CLR01**
19 (Fig. 7b). The most efficient esters carried unbranched C4 units (**CLR01-e** and **-f**) and inhibit
20 HIV-1 infection at ~4-5-fold lower concentrations than **CLR01**. The **CLR01** analog with C18
21 chains, **CLR01-i**, was highly cytotoxic (Fig. 7b and Supplementary Fig. 12). The Selectivity
22 Index of the modified tweezers confirmed that the advanced tweezers with lipid anchors, in
23 particular **CLR01-e** and **-f**, are indeed superior to their ancestor CLR01 (Supplementary Fig.
24 12b). The only exception was **CLR01-i**, which was cytotoxic (Supplementary Fig. 12b).
25 Liposomal dye-leakage assays demonstrated that most **CLR01** derivatives induced a more rapid
26 and more effective membrane disruption as parental **CLR01** (Fig. 7c, Supplementary Figure
27 7d). Moreover, we observed a statistically significant ($p < 0.05$) correlation between the anti-
28 HIV activity and potency in liposome disruption, supporting the above-detailed mechanism
29 (Fig. 7d). These findings show one way for improving efficacy of tweezers, namely by the
30 introduction of membrane-active components to the parent tweezer unit. We are now
31 performing a broad screening of such modified tweezers to identify powerful nontoxic
32 candidates.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 7. Advanced molecular tweezer derivatives with two aliphatic ester arms display improved activity against HIV-1 infection. (a) Chemical structures of the new two-armed tweezer derivatives developed from the parent phosphate tweezer CLR01. (b) Effect of the new tweezers on HIV-1 infection. HIV-1 was exposed to tweezer at indicated concentrations and then used to infect TZM-bl cells. Infection rates were determined 2 days later by quantifying β -gal. activity. Shown are mean values derived from 1-3 experiments each performed in triplicates \pm SEM. (c) Liposome dye leakage assay of DOPC/SM/Chol (45/25/30 mol%) liposomes filled with 50 mM carboxyfluorescein. Compounds were added after measuring baseline fluorescence for 5 min (first dotted line) and after 30 min incubation with compounds, Triton X-100 was added to 1% final concentration to measure fluorescence intensity after full leakage in each well (second dotted line). Fluorescence values were baseline-subtracted (before addition of compounds) and normalized to maximum fluorescence obtained after addition of Triton X-100. Values represent means \pm SD (n = 3). (d) Correlation of anti-HIV IC₅₀ values from (b) and EC₅₀ measured in the liposome leakage assays (c). Derivates g and h were excluded, as 50% leakage was not reached and thus no EC₅₀ calculated.

Discussion

The molecular tweezer **CLR01** is a well-established inhibitor of abnormal protein self-assembly and has been found to inhibit the formation of toxic oligomers and aggregates of multiple disease-associated proteins including those involved in Alzheimer's disease^{38,39} and Parkinson's disease^{10,40,41}. Moreover, **CLR01** also blocks formation of seminal amyloid fibrils¹⁴ that are potent enhancers of Ebola Virus and HIV-1 infection^{15,21}. The anti-amyloid activity is achieved by reversible inclusion of positively charged amino acid residues inside the tweezer cavity, primarily Lys and to a lower extent Arg¹⁴. More recently, we demonstrated that **CLR01** also acts as broad-spectrum inhibitor of enveloped viruses, including HIV-1, ZIKV and Ebola Virus²⁴. The exact mechanism underlying the antiviral activity of **CLR01**, was, however, unclear.

We show here that the anti-amyloid and the antiviral activity are separable functions of **CLR01**. **CLR05**, a tweezer derivative that carries methylene carboxylates instead of phosphates, does not encapsulate Lys/Arg residues and consequently displays no anti-amyloid activity. However, like **CLR01**, **CLR05** suppresses virus infection in a dose-dependent manner. This finding demonstrates that Lys/Arg inclusion is not necessary for virus inhibition. On the other hand, the phosphate clip **PC**, a structurally related phosphorylated derivative with a modified open cavity, was devoid of both activities, indicating that the closed horseshoe-shaped cavity of the tweezers plays a key role in viral membrane destabilization by **CLR01** and **CLR05**. In agreement with these results, only **CLR01**, but not **CLR05** and **PC**, effectively prevented complex formation between seminal fibrils and virions, and abrogated infectivity-enhancement. We conclude that the anti-amyloid activity relies on Lys/Arg inclusion inside the tweezer cavity, leads to a neutralized zeta potential of the fibrils, and eliminates their potential to carry virions to the cell membrane.

How do **CLR01** and **CLR05** destabilize and eventually disrupt the viral membrane? Through a combination of biomolecular simulations, model titrations (¹H NMR, fluorescence) and liposome experiments, we discovered that **CLR01**, **CLR05** and **PC** all engage lipid head-groups at the surface of biological and synthetic membranes. This supramolecular process involves encapsulation of the trimethylammonium moiety of the choline of DOPC or SM inside their cavities, which only occurs close to the membrane surface. Here, even the amphiphilic **CLR05** orients its methylene carboxylate arms towards the bulk water and thus exposes its cavity. Antiviral tweezers **CLR01** and **CLR05** induce a horizontal lipid orientation inside their closed cavities, which favors their insertion in the polar region of the outer leaflet and raises the local stress of the membrane. This rearrangement ultimately ruptures viral membranes – as visualized by cryo-TEM of **CLR01**-exposed HCMV particles - and diminishes viral infectivity. By contrast, the open **PC** cavity allows stress-free lipid insertion from below and hence does not affect viral membrane integrity explaining the lack of antiviral activity.

Experiments with fluorescent GUVs and liposomes suggest a profound difference between DOPC membranes, which remain intact after tweezer or clip exposure, and DOPC liposomes containing SM and Chol, which imitate the composition of viral membranes and are quickly disrupted at their phase boundaries between DOPC and lipid rafts when tweezers are added.


1
2
3 We explain this difference by the elevated surface tension already present in lipid rafts, which
4 is further increased after **CLR01** or **CLR05** insertion. Our findings also explain the minimal
5 cytotoxicity of tweezers¹⁴ because the surface tension of the ordinary cellular plasma membrane
6 is much lower than that of small nanometer-sized liposomal or viral membranes, which are
7 disrupted by **CLR01** or **CLR05**. In addition, we show by computational QM/MM modeling
8 and NMR experiments that the inclusion complexes with SM are intrinsically more stable than
9 those with DOPC, which is rationalized by a reduced competition between electrostatic and
10 dispersion forces and solvation effects in SM.
11
12
13
14

15 **CLR01** showed a modestly increased antiviral activity as compared to **CLR05**. Leakage assays
16 revealed that **CLR01** lyses DOPC/SM/Chol liposomes more rapidly and more effectively than
17 **CLR05**. Computational modelling and NMR titrations showed that **CLR05** is able to bind the
18 trimethylammonium cation of the choline head group also outside the cavity by way of a chelate
19 complex between its carboxylate tips. This binding mode is weaker, does not exert any strain
20 on the lipids inside the membrane and thus lowers the membrane destabilization efficiency.
21 Collectively, these data suggest that tweezer architecture and the direct inclusion of the choline
22 head-group inside the tweezer cavity are required for their biological effect. Importantly,
23 additional lipid anchor groups on the phosphate moieties further strengthen this effect (Fig. 7).
24
25
26
27

28 We also observed that some viruses need more tweezer to be disrupted than others. For
29 example, **CLR01** was more effective against HSV-2 than IAV (Fig. 6b). This difference could
30 be caused by distinct capsid/envelope packaging of various viruses, the overall virion
31 architecture, the membrane curvature and/or tension, or the accessibility of the viral membrane
32 because of the incorporation of viral and cellular proteins. Another explanation is that the total
33 number of infectious, sub-infectious or non-infectious particles as well as the absolute
34 infectious titer can vary greatly between different stocks of the same virus and even more
35 between different virus families. In the light of these differences, it is actually surprising that
36 all IC₅₀ values determined so far (in independent studies with different viruses) were always
37 between 5 μM and 50 μM^{14,24}. These findings further underline the proposed universal antiviral
38 mode of action: the direct interaction and disruption of the viral membrane by the tweezer. The
39 micromolar IC₅₀ values may reflect the large number of lipids in the membrane which must be
40 occupied by molecular tweezers before rupture occurs. An indication for this possibility comes
41 from elevated IC₅₀ levels observed when viral preparations contain large amounts of cellular
42 fragments (data not shown). However, **CLR01** binds very weakly to choline head groups (mM
43 *K_d* range) and in a fully reversible manner with fast exchange (averaged NMR signals). Only
44 when the surface tension exceeds the critical threshold, is the viral membrane disrupted
45 irreversibly.
46
47
48
49
50
51
52

53 In conclusion, **CLR01** and **CLR05** specifically target enveloped viruses by destroying the
54 integrity of the viral membrane (Fig. 8). Both tweezers do not affect “naked” EMCV or
55 Adenovirus infection but are active against all analyzed enveloped viruses including not only
56 well-known pathogens such as herpesviruses or HIV-1 but also emerging or reemerging viruses,
57 including Ebola and Zika virus. A series of two-armed new tweezers were synthesized based
58 on this mechanistic insight, which display significantly improved antiviral activities. Their
59
60

1
2
3 additional lipid anchors increase viral membrane destabilization, and opens the path for
4 structural optimization to more potent scaffolds. Our findings may be particularly useful for
5 prevention and treatment of viruses, where no specific antiviral therapy exists as with the
6 ongoing SARS-CoV-2/COVID-19 pandemic. Moreover, the apparent lack of toxicity in animal
7 models render molecular tweezers very promising lead compounds for a novel class of potential
8 broad-spectrum antivirals^{40,42–46}.
9
10
11
12



34 **Fig. 8. Schematic representation of virus disruption by molecular tweezers.** Tweezer molecules encapsulate
35 the phosphocholine head-groups of DOPC and SM in the outer lipid leaflet of the viral membrane,
36 thereby increasing the mechanical stress in the outer leaflet, which initiates the rupture of the viral membrane and
37 consequently loss of viral infectivity.
38

39 Safety

40 To the best of our knowledge, there are no unexpected, new, or significant hazards or risks
41 associated with the reported work.
42
43

44 Acknowledgements

45 M.H., T.W., L.W. and R.G. are part of the International Graduate School in Molecular Medicine
46 Ulm. R.G. was funded by a scholarship from the International Graduate School in Molecular
47 Medicine Ulm. P.W., J.M. and E.S-G. acknowledge funding by the DFG CRC1279. J.S. was
48 supported by a Bill and Melinda Gates Foundation Grand Challenges Explorations Award and
49 NIH grant R21HD074510. J.M. acknowledges funding by the Volkswagen Foundation and the
50 EU's Horizon 2020 research and innovation programme (Fight-nCoV, 101003555. J.A.M. is
51 funded by a grant from the Medical Faculty of Ulm University and indebted to the Baden-
52 Württemberg Stiftung for the financial support of this research project by the Eliteprogramme
53 for Postdocs. A.S, C.H. and T.S. as well as K.B.R. and E.S-G. gratefully acknowledge funding
54 by the DFG CRC 1093 "Supramolecular Chemistry on Proteins" (A3 and A8). E.S-G. and R.W.
55 acknowledge the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
56 under Germany's Federal and State Excellence Strategy – EXC-2033 – Projektnummer
57
58
59
60

390677874. E.S-G. also acknowledges the Boehringer Ingelheim Foundation (Plus-3 grant) and the computational time provided by the Computing and Data Facility of the Max Planck Society and the supercomputer magnitUDE of the University of Duisburg-Essen. G.B. acknowledges support from NIH/NIA grant R01AG050721. We thank Stefan Pöhlmann for providing the SARS-CoV-2 spike expression plasmid.

Corresponding Authors

Jan Münch, jan.muench@uni-ulm.de

Elsa Sanchez-Garcia, elsa.sanchez-garcia@uni-due.de

James Shorter, jshorter@pennmedicine.upenn.edu

Thomas Schrader, thomas.schrader@uni-due.de

Author Contribution note

Tatjana Weil, Rüdiger Groß, Annika Röcker, and Kenny Bravo-Rodriguez contributed equally to this work.

Associated Content.

1. Material and Methods
2. Supplementary Figures
3. Supplementary Tables
4. References of Material and Methods

This information is available free of charge on the ACS website (<http://pubs.acs.org>)

Competing interests

A.R., C.H., A.S., T.S., G.B., and J.M. are inventors on the provisional patent application 62/692,479 “New Molecular Tweezers against Neurological Disorders and Viral Infections”.

Statistical information

All data were analyzed using GraphPad Prism version 7.03 for Windows, GraphPad Software, La Jolla California USA (www.graphpad.com). Significance levels were calculated using one-way analysis of variance (ANOVA) (non-parametric, grouped), followed by Bonferroni's or Dunnett's multiple comparison test (indicated in figure legends). P values of < 0.01 were considered significant (*, $p < 0.01$ **, $p < 0.001$ ***, $p < 0.0001$). In some cases, unpaired t-tests (parametric, two-tailored) were used to compare a buffer control to compound-treated conditions.

References


- (1) Jackman, J. A.; Shi, P. Y.; Cho, N. J. Targeting the Achilles Heel of Mosquito-Borne Viruses for Antiviral Therapy. *ACS Infect. Dis.* **2019**, *5* (1), 4–8. <https://doi.org/10.1021/acsinfecdis.8b00286>.

- 1
2
3 (2) Vigant, F.; Santos, N. C.; Lee, B. Broad-Spectrum Antivirals against Viral Fusion.
4 *Nature Reviews Microbiology*. Nature Publishing Group July 18, 2015, pp 426–437.
5 <https://doi.org/10.1038/nrmicro3475>.
- 6
7 (3) Liao, M.; Kielian, M. Domain III from Class II Fusion Proteins Functions as a
8 Dominant-Negative Inhibitor of Virus Membrane Fusion. *J. Cell Biol.* **2005**, *171* (1),
9 111–120. <https://doi.org/10.1083/jcb.200507075>.
- 10
11 (4) Koehler, J. W.; Smith, J. M.; Ripoll, D. R.; Spik, K. W.; Taylor, S. L.; Badger, C. V.;
12 Grant, R. J.; Ogg, M. M.; Wallqvist, A.; Guttieri, M. C.; Garry, R. F.; Schmaljohn, C.
13 S. A Fusion-Inhibiting Peptide against Rift Valley Fever Virus Inhibits Multiple,
14 Diverse Viruses. *PLoS Negl. Trop. Dis.* **2013**, *7* (9), e2430.
15 <https://doi.org/10.1371/journal.pntd.0002430>.
- 16
17 (5) Diwaker, D.; Mishra, K. P.; Ganju, L. Potential Roles of Protein Disulphide Isomerase
18 in Viral Infections. *Acta Virol.* **2013**, *57* (3), 293–304.
19 https://doi.org/10.4149/av_2013_03_293.
- 20
21 (6) Badani, H.; Garry, R. F.; Wimley, W. C. Peptide Entry Inhibitors of Enveloped
22 Viruses: The Importance of Interfacial Hydrophobicity. *Biochimica et Biophysica Acta*
23 *- Biomembranes*. 2014, pp 2180–2197. <https://doi.org/10.1016/j.bbamem.2014.04.015>.
- 24
25 (7) Pollock, S.; Branza-Nichita, N.; Böhmer, A.; Radulescu, C.; Dwek, R. A.; Zitzmann, N.
26 Polyunsaturated Liposomes Are Antiviral against Hepatitis B and C Viruses and HIV
27 by Decreasing Cholesterol Levels in Infected Cells. *Proc. Natl. Acad. Sci. U. S. A.*
28 **2010**, *107* (40), 17176–17181. <https://doi.org/10.1073/pnas.1009445107>.
- 29
30 (8) St. Vincent, M. R.; Colpitts, C. C.; Ustinov, A. V.; Muqadas, M.; Joyce, M. A.; Barsby,
31 N. L.; Epand, R. F.; Epand, R. M.; Khrmyshev, S. A.; Valueva, O. A.; Korshun, V.
32 A.; Tyrrell, D. L. J.; Schang, L. M. Rigid Amphiphathic Fusion Inhibitors, Small
33 Molecule Antiviral Compounds against Enveloped Viruses. *Proc. Natl. Acad. Sci. U. S.*
34 *A.* **2010**, *107* (40), 17339–17344. <https://doi.org/10.1073/pnas.1010026107>.
- 35
36 (9) Hollmann, A.; Castanho, M. A. R. B.; Lee, B.; Santos, N. C. Singlet Oxygen Effects on
37 Lipid Membranes: Implications for the Mechanism of Action of Broad-Spectrum Viral
38 Fusion Inhibitors. *Biochem. J.* **2014**, *459* (1), 161–170.
39 <https://doi.org/10.1042/BJ20131058>.
- 40
41 (10) Sinha, S.; Lopes, D. H. J.; Du, Z.; Pang, E. S.; Shanmugam, A.; Lomakin, A.;
42 Talbiersky, P.; Tennstaedt, A.; McDaniel, K.; Bakshi, R.; Kuo, P. Y.; Ehrmann, M.;
43 Benedek, G. B.; Loo, J. A.; Klärner, F. G.; Schrader, T.; Wang, C.; Bitan, G. Lysine-
44 Specific Molecular Tweezers Are Broad-Spectrum Inhibitors of Assembly and Toxicity
45 of Amyloid Proteins. *J. Am. Chem. Soc.* **2011**, *133* (42), 16958–16969.
46 <https://doi.org/10.1021/ja206279b>.
- 47
48 (11) Attar, A.; Bitan, G. Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein
49 Oligomers by “Molecular Tweezers” - from the Test Tube to Animal Models. *Curr.*
50 *Pharm. Des.* **2014**, *20* (15), 2469–2483.
51 <https://doi.org/10.2174/13816128113199990496>.
- 52
53 (12) Schrader, T.; Bitan, G.; Klärner, F. G. Molecular Tweezers for Lysine and Arginine-
54 Powerful Inhibitors of Pathologic Protein Aggregation. *Chem. Commun.* **2016**, *52* (76),
55 11318–11334. <https://doi.org/10.1039/c6cc04640a>.
- 56
57 (13) Hadrovic, I.; Rebmann, P.; Klärner, F.-G.; Bitan, G.; Schrader, T. Molecular Lysine
58 Tweezers Counteract Aberrant Protein Aggregation. *Front. Chem.* **2019**, *7*, 657.
59 <https://doi.org/10.3389/FCHEM.2019.00657>.
- 60
61 (14) Lump, E.; Castellano, L. M.; Meier, C.; Seeliger, J.; Erwin, N.; Sperlich, B.; Stürzel, C.
62 M.; Usmani, S.; Hammond, R. M.; Von Einem, J.; Gerold, G.; Kreppel, F.; Bravo-
63 Rodriguez, K.; Pietschmann, T.; Holmes, V. M.; Palesch, D.; Zirafi, O.; Weissman, D.;
64 Sowislok, A.; Wettig, B.; Heid, C.; Kirchhoff, F.; Weil, T.; Klärner, F. G.; Schrader,
65 T.; Bitan, G.; Sanchez-Garcia, E.; Winter, R.; Shorter, J.; Munch, J. A Molecular

- 1
2
3 Tweezer Antagonizes Seminal Amyloids and HIV Infection. *Elife* **2015**, *4*
4 (AUGUST2015), 1–33. <https://doi.org/10.7554/eLife.05397>.
- 5
6 (15) Münch, J.; Rücker, E.; Ständker, L.; Adermann, K.; Goffinet, C.; Schindler, M.;
7 Wildum, S.; Chinnadurai, R.; Rajan, D.; Specht, A.; Giménez-Gallego, G.; Sánchez, P.
8 C.; Fowler, D. M.; Koulov, A.; Kelly, J. W.; Mothes, W.; Grivel, J. C.; Margolis, L.;
9 Keppler, O. T.; Forssmann, W. G.; Kirchhoff, F. Semen-Derived Amyloid Fibrils
10 Drastically Enhance HIV Infection. *Cell* **2007**, *131* (6), 1059–1071.
11 <https://doi.org/10.1016/j.cell.2007.10.014>.
- 12
13 (16) Roan, N. R.; Müller, J. A.; Liu, H.; Chu, S.; Arnold, F.; Stürzel, C. M.; Walther, P.;
14 Dong, M.; Witkowska, H. E.; Kirchhoff, F.; Münch, J.; Greene, W. C. Peptides
15 Released by Physiological Cleavage of Semen Coagulum Proteins Form Amyloids
16 That Enhance HIV Infection. *Cell Host Microbe* **2011**, *10* (6), 541–550.
17 <https://doi.org/10.1016/j.chom.2011.10.010>.
- 18
19 (17) Usmani, S. M.; Zirafi, O.; Müller, J. A.; Sandi-Monroy, N. L.; Yadav, J. K.; Meier, C.;
20 Weil, T.; Roan, N. R.; Greene, W. C.; Walther, P.; Nilsson, K. P. R.; Hammarström, P.;
21 Wetzel, R.; Pilcher, C. D.; Gagsteiger, F.; Fändrich, M.; Kirchhoff, F.; Münch, J.
22 Direct Visualization of HIV-Enhancing Endogenous Amyloid Fibrils in Human Semen.
23 *Nat. Commun.* **2014**, *5* (1), 3508. <https://doi.org/10.1038/ncomms4508>.
- 24
25 (18) Kim, K. A.; Yolamanova, M.; Zirafi, O.; Roan, N. R.; Staendker, L.; Forssmann, W.
26 G.; Burgener, A.; Dejucq-Rainsford, N.; Hahn, B. H.; Shaw, G. M.; Greene, W. C.;
27 Kirchhoff, F.; Münch, J. Semen-Mediated Enhancement of HIV Infection Is Donor-
28 Dependent and Correlates with the Levels of SEVI. *Retrovirology* **2010**, *7* (1), 55.
29 <https://doi.org/10.1186/1742-4690-7-55>.
- 30
31 (19) Castellano, L. M.; Shorter, J. The Surprising Role of Amyloid Fibrils in HIV Infection.
32 *Biology*. May 29, 2012, pp 58–80. <https://doi.org/10.3390/biology1010058>.
- 33
34 (20) Torres, L.; Ortiz, T.; Tang, Q. Enhancement of Herpes Simplex Virus (HSV) Infection
35 by Seminal Plasma and Semen Amyloids Implicates a New Target for the Prevention
36 of HSV Infection. *Viruses* **2015**, *7* (4), 2057–2073. <https://doi.org/10.3390/v7042057>.
- 37
38 (21) Bart, S. M.; Cohen, C.; Dye, J. M.; Shorter, J.; Bates, P. Enhancement of Ebola Virus
39 Infection by Seminal Amyloid Fibrils. *Proc. Natl. Acad. Sci.* **2018**, *115* (28), 7410–
40 7415. <https://doi.org/10.1073/pnas.1721646115>.
- 41
42 (22) Roan, N. R.; Munch, J.; Arhel, N.; Mothes, W.; Neidleman, J.; Kobayashi, A.; Smith-
43 McCune, K.; Kirchhoff, F.; Greene, W. C. The Cationic Properties of SEVI Underlie
44 Its Ability To Enhance Human Immunodeficiency Virus Infection. *J. Virol.* **2009**, *83*
45 (1), 73–80. <https://doi.org/10.1128/jvi.01366-08>.
- 46
47 (23) Arnold, F.; Schnell, J.; Zirafi, O.; Sturzel, C.; Meier, C.; Weil, T.; Standker, L.;
48 Forssmann, W.-G.; Roan, N. R.; Greene, W. C.; Kirchhoff, F.; Munch, J. Naturally
49 Occurring Fragments from Two Distinct Regions of the Prostatic Acid Phosphatase
50 Form Amyloidogenic Enhancers of HIV Infection. *J. Virol.* **2012**, *86* (2), 1244–1249.
51 <https://doi.org/10.1128/jvi.06121-11>.
- 52
53 (24) Röcker, A. E.; Müller, J. A.; Dietzel, E.; Harms, M.; Krüger, F.; Heid, C.; Sowislok,
54 A.; Riber, C. F.; Kupke, A.; Lippold, S.; von Einem, J.; Beer, J.; Knöll, B.; Becker, S.;
55 Schmidt-Chanasit, J.; Otto, M.; Vapalahti, O.; Zelikin, A. N.; Bitan, G.; Schrader, T.;
56 Münch, J. The Molecular Tweezer CLR01 Inhibits Ebola and Zika Virus Infection.
57 *Antiviral Res.* **2018**, *152*, 26–35. <https://doi.org/10.1016/j.antiviral.2018.02.003>.
- 58
59 (25) Dutt, S.; Wilch, C.; Gersthagen, T.; Talbiersky, P.; Bravo-Rodriguez, K.; Hanni, M.;
60 Sánchez-García, E.; Ochsenfeld, C.; Klärner, F. G.; Schrader, T. Molecular Tweezers
with Varying Anions: A Comparative Study. *J. Org. Chem.* **2013**, *78* (13), 6721–6734.
<https://doi.org/10.1021/jo4009673>.
- (26) Talbiersky, P.; Bastkowski, F.; Klärner, F. G.; Schrader, T. Molecular Clip and
Tweezer Introduce New Mechanisms of Enzyme Inhibition. *J. Am. Chem. Soc.* **2008**,

- 1
2
3 130 (30), 9824–9828. <https://doi.org/10.1021/ja801441j>.
- 4 (27) Polkowska, J.; Bastkowski, F.; Schrader, T.; Klärner, F.-G.; Zienau, J.; Koziol, F.;
5 Ochsenfeld, C. A Combined Experimental and Theoretical Study of the PH-Dependent
6 Binding Mode of NAD⁺ by Water-Soluble Molecular Clips. *J. Phys. Org. Chem.* **2009**,
7 22 (8), 779–790. <https://doi.org/10.1002/poc.1519>.
- 8 (28) Jasper, C.; Schrader, T.; Panitzky, J.; Klärner, F.-G. Selective Complexation of N-
9 Alkylpyridinium Salts: Recognition of NAD⁺ in Water. *Angew. Chem. Int. Ed. Engl.*
10 **2002**, 41 (8), 1355–1358.
- 11 (29) Schrader, T.; Fokkens, M.; Klärner, F.-G.; Polkowska, J.; Bastkowski, F. Inclusion of
12 Thiamine Diphosphate and S-Adenosylmethionine at Their Chemically Active Sites. *J.*
13 *Org. Chem.* **2005**, 70 (25), 10227–10237. <https://doi.org/10.1021/jo0511896>.
- 14 (30) French, K. C.; Makhatadze, G. I. Core Sequence of Papf39 Amyloid Fibrils and
15 Mechanism of Ph-Dependent Fibril Formation: The Role of Monomer Conformation.
16 *Biochemistry* **2012**, 51 (51), 10127–10136. <https://doi.org/10.1021/bi301406d>.
- 17 (31) Lorizate, M.; Sachsenheimer, T.; Glass, B.; Habermann, A.; Gerl, M. J.; Kräusslich, H.
18 G.; Brügger, B. Comparative Lipidomics Analysis of HIV-1 Particles and Their
19 Producer Cell Membrane in Different Cell Lines. *Cell. Microbiol.* **2013**, 15 (2), 292–
20 304. <https://doi.org/10.1111/cmi.12101>.
- 21 (32) Thaa, B.; Siche, S.; Herrmann, A.; Veit, M. Acylation and Cholesterol Binding Are Not
22 Required for Targeting of Influenza A Virus M2 Protein to the Hemagglutinin-Defined
23 Budozone. *FEBS Lett.* **2014**, 588 (6), 1031–1036.
24 <https://doi.org/10.1016/j.febslet.2014.02.014>.
- 25 (33) Takahashi, T.; Suzuki, T. Function of Membrane Rafts in Viral Lifecycles and Host
26 Cellular Response. *Biochem. Res. Int.* **2011**, 2011.
27 <https://doi.org/10.1155/2011/245090>.
- 28 (34) Bavari, S.; Bosio, C. M.; Wiegand, E.; Ruthel, G.; Will, A. B.; Geisbert, T. W.; Hevey,
29 M.; Schmaljohn, C.; Schmaljohn, A.; Javad Aman, M. Lipid Raft Microdomains: A
30 Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses. *J. Exp.*
31 *Med.* **2002**, 195 (5), 593–602. <https://doi.org/10.1084/jem.20011500>.
- 32 (35) Brügger, B.; Glass, B.; Haberkant, P.; Leibrecht, I.; Wieland, F. T.; Kräusslich, H. G.
33 The HIV Lipidome: A Raft with an Unusual Composition. *Proc. Natl. Acad. Sci. U. S.*
34 *A.* **2006**, 103 (8), 2641–2646. <https://doi.org/10.1073/pnas.0511136103>.
- 35 (36) Chan, R.; Uchil, P. D.; Jin, J.; Shui, G.; Ott, D. E.; Mothes, W.; Wenk, M. R.
36 Retroviruses Human Immunodeficiency Virus and Murine Leukemia Virus Are
37 Enriched in Phosphoinositides. *J. Virol.* **2008**, 82 (22), 11228–11238.
38 <https://doi.org/10.1128/jvi.00981-08>.
- 39 (37) Van Genderen, I. L.; Brandimarti, R.; Torrasi, M. R.; Campadelli, G.; Van Meer, G.
40 The Phospholipid Composition of Extracellular Herpes Simplex Virions Differs from
41 That of Host Cell Nuclei. *Virology* **1994**, 200 (2), 831–836.
42 <https://doi.org/10.1006/viro.1994.1252>.
- 43 (38) Sinha, S.; Du, Z.; Maiti, P.; Klärner, F. G.; Schrader, T.; Wang, C.; Bitan, G.
44 Comparison of Three Amyloid Assembly Inhibitors: The Sugar Scyllo- Inositol, the
45 Polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01. *ACS Chem.*
46 *Neurosci.* **2012**, 3 (6), 451–458. <https://doi.org/10.1021/cn200133x>.
- 47 (39) Zheng, X.; Liu, D.; Klärner, F. G.; Schrader, T.; Bitan, G.; Bowers, M. T. Amyloid β -
48 Protein Assembly: The Effect of Molecular Tweezers CLR01 and CLR03. *J. Phys.*
49 *Chem. B* **2015**, 119 (14), 4831–4841. <https://doi.org/10.1021/acs.jpcc.5b00692>.
- 50 (40) Prabhudesai, S.; Sinha, S.; Attar, A.; Kotagiri, A.; Fitzmaurice, A. G.; Lakshmanan, R.;
51 Ivanova, M. I.; Loo, J. A.; Klärner, F. G.; Schrader, T.; Stahl, M.; Bitan, G.; Bronstein,
52 J. M. A Novel “Molecular Tweezer” Inhibitor of α -Synuclein Neurotoxicity in Vitro
53 and in Vivo. *Neurotherapeutics* **2012**, 9 (2), 464–476. <https://doi.org/10.1007/s13311->
54
55
56
57
58
59
60

- 1
2
3 012-0105-1.
- 4 (41) Acharya, S.; Lapidus, L. J.; Safaie, B. M.; Attar, A.; Bitan, G.; Wongkongkathep, P.;
5 Loo, J. A.; Ivanova, M. I.; Klärner, F.-G.; Schrader, T. Molecular Basis for Preventing
6 α -Synuclein Aggregation by a Molecular Tweezer. *J. Biol. Chem.* **2014**, *289* (15),
7 10727–10737. <https://doi.org/10.1074/jbc.M113.524520>.
- 8 (42) Attar, A.; Chan, W. T. C.; Klärner, F. G.; Schrader, T.; Bitan, G. Safety and
9 Pharmacological Characterization of the Molecular Tweezer CLR01-A Broad-
10 Spectrum Inhibitor of Amyloid Proteins' Toxicity. *BMC Pharmacol. Toxicol.* **2014**, *15*
11 (1), 23. <https://doi.org/10.1186/2050-6511-15-23>.
- 12 (43) Attar, A.; Ripoli, C.; Riccardi, E.; Maiti, P.; Li Puma, D. D.; Liu, T.; Hayes, J.; Jones,
13 M. R.; Lichti-Kaiser, K.; Yang, F.; Gale, G. D.; Tseng, C. -h.; Tan, M.; Xie, C.-W.;
14 Straudinger, J. L.; Klärner, F.-G.; Schrader, T.; Frautschy, S. A.; Grassi, C.; Bitan, G.
15 Protection of Primary Neurons and Mouse Brain from Alzheimer's Pathology by
16 Molecular Tweezers. *Brain* **2012**, *135* (12), 3735–3748.
17 <https://doi.org/10.1093/brain/aws289>.
- 18 (44) Ferreira, N.; Pereira-Henriques, A.; Attar, A.; Klärner, F. G.; Schrader, T.; Bitan, G.;
19 Gales, L.; Saraiva, M. J.; Almeida, M. R. Molecular Tweezers Targeting Transthyretin
20 Amyloidosis. *Neurotherapeutics* **2014**, *11* (2), 450–461.
21 <https://doi.org/10.1007/s13311-013-0256-8>.
- 22 (45) Fogerson, S. M.; van Brummen, A. J.; Busch, D. J.; Allen, S. R.; Roychaudhuri, R.;
23 Banks, S. M. L.; Klärner, F. G.; Schrader, T.; Bitan, G.; Morgan, J. R. Reducing
24 Synuclein Accumulation Improves Neuronal Survival after Spinal Cord Injury. *Exp.*
25 *Neurol.* **2016**, *278*, 105–115. <https://doi.org/10.1016/j.expneurol.2016.02.004>.
- 26 (46) Lulla, A.; Barnhill, L.; Bitan, G.; Ivanova, M. I.; Nguyen, B.; O'Donnell, K.; Stahl, M.
27 C.; Yamashiro, C.; Klärner, F. G.; Schrader, T.; Sagasti, A.; Bronstein, J. M.
28 Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-
29 Dependent in Zebrafish Embryos. *Environ. Health Perspect.* **2016**, *124* (11), 1766–
30 1775. <https://doi.org/10.1289/EHP141>.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Schematic representation of virus disruption by molecular tweezers. Tweezer molecules encapsulate the phosphocholine head-groups of DOPC and SM in the outer lipid leaflet of the viral membrane, thereby increasing the mechanical stress in the outer leaflet, which initiates the rupture of the viral membrane and consequently loss of viral infectivity.